000294843 001__ 294843
000294843 005__ 20250507114418.0
000294843 0247_ $$2doi$$a10.1097/RLI.0000000000001145
000294843 0247_ $$2pmid$$apmid:39644107
000294843 0247_ $$2ISSN$$a0020-9996
000294843 0247_ $$2ISSN$$a1536-0210
000294843 0247_ $$2altmetric$$aaltmetric:171805831
000294843 037__ $$aDKFZ-2024-02553
000294843 041__ $$aEnglish
000294843 082__ $$a610
000294843 1001_ $$00000-0002-5550-0489$$aKarimian-Jazi, Kianush$$b0
000294843 245__ $$aDifferentiating Glioma Recurrence and Pseudoprogression by APTw CEST MRI.
000294843 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2025
000294843 3367_ $$2DRIVER$$aarticle
000294843 3367_ $$2DataCite$$aOutput Types/Journal article
000294843 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746611013_3746
000294843 3367_ $$2BibTeX$$aARTICLE
000294843 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294843 3367_ $$00$$2EndNote$$aJournal Article
000294843 500__ $$a#EA:B320#LA:D170# / 2025 Jun 1;60(6):414-422
000294843 520__ $$aRecurrent glioma is highly treatment resistant due to its metabolic, cellular, and molecular heterogeneity and invasiveness. Tumor monitoring by conventional MRI has shortcomings to assess these key glioma characteristics. Recent studies introduced chemical exchange saturation transfer for metabolic imaging in oncology and assessed its diagnostic value for newly diagnosed glioma. This prospective study investigates amide proton transfer-weighted (APTw) MRI at 3 T as an imaging biomarker to elucidate the molecular heterogeneity and invasion patterns of recurrent glioma in comparison to pseudoprogression (PsPD).We performed a monocenter, prospective trial and screened 371 glioma patients who received tumor monitoring between August 2021 and March 2024 at our institution. The study included IDH wildtype astrocytoma and IDH mutant astrocytoma and oligodendroglioma, graded according to the WHO 2021 classification. Patients had received clinical standard of care treatment including surgical resection and radiochemotherapy prior to study inclusion. Patients were monitored by 3 monthly MRI follow-up imaging, and response assessment was performed according to the RANO criteria. Within this cohort, we identified 30 patients who presented with recurrent glioma and 12 patients with PsPD. In addition to standard anatomical sequences (FLAIR and T1-w Gd-enhanced sequences), MRI included APTw imaging. After sequence co-registration, semiautomated segmentation was performed of the FLAIR lesion, CE lesion, resection cavity, and the contralateral normal-appearing white matter, and APTw signals were quantified in these regions of interest.APTw values were highest in solid, Gd-enhancing tumor parts as compared with the nonenhancing FLAIR lesion (APTw: 1.99% vs 1.36%, P = 0.001), whereas there were no detectable APTw alterations in the normal-appearing white matter (APTw: 0.005%, P < 0.001 compared with FLAIR). Patients with progressive disease had higher APTw levels compared with patients with PsPD (APTw: 1.99% vs 1.26%, P = 0.008). Chemical exchange saturation transfer identified heterogeneity within the FLAIR lesion that was not detectable by conventional sequences. There were also focal APTw signal peaks within contrast enhancing lesions as putative metabolic hotspots within recurrent glioma. The resection cavity developed an APTw increase at recurrence that was not detectable prior to recurrence nor in patients with PsPD (APTw before recurrence: 0.6% vs 2.68% at recurrence, P = 0.03).Our study shows that APTw imaging can differentiate PD and PsPD. We identify previously undetectable imaging patterns during glioma recurrence, which include alterations within resection cavity associated with disease progression. Our work highlights the clinical potential of APTw imaging for glioma monitoring and further establishes it as an imaging biomarker in neuro-oncology.
000294843 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000294843 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294843 7001_ $$aEnbergs, Noah$$b1
000294843 7001_ $$00009-0007-9337-6232$$aGolubtsov, Evgeny$$b2
000294843 7001_ $$aSchregel, Katharina$$b3
000294843 7001_ $$aUngermann, Johannes$$b4
000294843 7001_ $$aFels-Palesandro, Hannah$$b5
000294843 7001_ $$aSchwarz, Daniel$$b6
000294843 7001_ $$aSturm, Volker$$b7
000294843 7001_ $$aKernbach, Julius M$$b8
000294843 7001_ $$aBatra, David$$b9
000294843 7001_ $$0P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aIppen, Franziska$$b10
000294843 7001_ $$aPflüger, Irada$$b11
000294843 7001_ $$0P:(DE-He78)857bbcdb8f5f582e00795df8b957767d$$avon Knebel Doeberitz, Nikolaus$$b12$$udkfz
000294843 7001_ $$aHeiland, Sabine$$b13
000294843 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b14$$udkfz
000294843 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b15$$udkfz
000294843 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b16$$udkfz
000294843 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b17$$udkfz
000294843 7001_ $$0P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aPaech, Daniel$$b18$$udkfz
000294843 7001_ $$aBendszus, Martin$$b19
000294843 7001_ $$0P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aBreckwoldt, Michael$$b20$$eLast author$$udkfz
000294843 773__ $$0PERI:(DE-600)2041543-6$$a10.1097/RLI.0000000000001145$$n6$$p414-422$$tInvestigative radiology$$v60$$x0020-9996$$y2025
000294843 909CO $$ooai:inrepo02.dkfz.de:294843$$pVDB
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b769be55bb53da2335ffbfdab5ddb1b6$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)857bbcdb8f5f582e00795df8b957767d$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000294843 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ba5b48bd126214d9cb66291fa4ae303$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000294843 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000294843 9141_ $$y2024
000294843 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-24$$wger
000294843 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINVEST RADIOL : 2022$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000294843 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINVEST RADIOL : 2022$$d2023-10-24
000294843 9202_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x0
000294843 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000294843 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000294843 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000294843 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x3
000294843 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lKKE Neuroimmunologie und Hirntumorimmunologie$$x4
000294843 9200_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000294843 980__ $$ajournal
000294843 980__ $$aVDB
000294843 980__ $$aI:(DE-He78)B320-20160331
000294843 980__ $$aI:(DE-He78)HD01-20160331
000294843 980__ $$aI:(DE-He78)B300-20160331
000294843 980__ $$aI:(DE-He78)E010-20160331
000294843 980__ $$aI:(DE-He78)D170-20160331
000294843 980__ $$aUNRESTRICTED